KDM4A-driven SMAD5/TGFβ axis activation as a therapeutic target in cholangiocarcinoma: mechanistic insights and translational implications
In summary, KDM4A promotes the development of cholangiocarcinoma by regulating SMAD5 to activate the TGFβ pathway. The KDM4A inhibitor JIB-04 shows potential in inhibiting cholangiocarcinoma progression, providing a rationale for the epigenetic therapy of cholangiocarcinoma.
Authors
- Wenzheng Liu
- Yongjun Chen
- Guanhua Wu (ORCID: https://orcid.org/0000-0001-6285-9337)
- Qi Wang (ORCID: https://orcid.org/0000-0002-1973-8510)
- Fei Xiong (ORCID: https://orcid.org/0000-0002-4280-5734)
- Junsheng Chen (ORCID: https://orcid.org/0000-0002-2934-8030)
- Bing Wang (ORCID: https://orcid.org/0000-0003-4945-7725)
- Yiyang Kuai
- Da Wang (ORCID: https://orcid.org/0000-0002-3376-5275)
Institutions
- Capital Medical University (CN)
- Beijing Friendship Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cell & Bioscience
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s13578-025-01472-0
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China